{"id":7544,"date":"2020-06-15T14:58:31","date_gmt":"2020-06-15T21:58:31","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=7544"},"modified":"2021-03-25T14:59:16","modified_gmt":"2021-03-25T21:59:16","slug":"first-clinical-use-of-lenzilumab-to-neutralize-gm-csf-in-patients-with-severe-and-critical-covid-19-pneumonia","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/06\/15\/first-clinical-use-of-lenzilumab-to-neutralize-gm-csf-in-patients-with-severe-and-critical-covid-19-pneumonia\/","title":{"rendered":"First Clinical Use of\u00a0Lenzilumab\u00a0to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"34\" data-aria-posinset=\"2019\" data-aria-level=\"1\"><i><span data-contrast=\"none\">[pre-print, not peer reviewed]<\/span><\/i><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">Temesgen et al.\u00a0<\/span><span data-contrast=\"auto\">reported the use of\u00a0lenzilumab, an anti- GM-CSF monoclonal antibody, in 12 patients with severe COVID-19 pneumonia.\u00a0<\/span><span data-contrast=\"auto\">Of the 12 treated patients,\u00a0<\/span><span data-contrast=\"auto\">11 (92%) patients had significantly improved clinical outcomes. There were no treatment-<\/span><span data-contrast=\"auto\">related\u00a0<\/span><span data-contrast=\"auto\">adverse events and no\u00a0<\/span><span data-contrast=\"auto\">deaths<\/span><span data-contrast=\"auto\">.\u00a0<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Temesgen et al. (June 12, 2020). First Clinical Use of\u00a0Lenzilumab\u00a0to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia. Pre-print\u00a0downloaded June 15 from\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2020.06.08.20125369\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1101\/2020.06.08.20125369<\/span><\/a><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[pre-print, not peer reviewed]\u00a0Temesgen et al.\u00a0reported the use of\u00a0lenzilumab, an anti- GM-CSF monoclonal antibody, in 12 patients with severe COVID-19 pneumonia.\u00a0Of the 12 treated patients,\u00a011 (92%) patients had significantly improved clinical outcomes. There were no treatment-related\u00a0adverse events and no\u00a0deaths.\u00a0\u00a0 Temesgen et al. (June 12, 2020). First Clinical Use of\u00a0Lenzilumab\u00a0to Neutralize GM-CSF in Patients with Severe&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/06\/15\/first-clinical-use-of-lenzilumab-to-neutralize-gm-csf-in-patients-with-severe-and-critical-covid-19-pneumonia\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[19],"class_list":["post-7544","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=7544"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7544\/revisions"}],"predecessor-version":[{"id":7545,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7544\/revisions\/7545"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=7544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=7544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=7544"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=7544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}